GSA Capital Partners LLP Has $1.16 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)

GSA Capital Partners LLP raised its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 9.0% in the 1st quarter, HoldingsChannel reports. The firm owned 52,448 shares of the company’s stock after purchasing an additional 4,352 shares during the quarter. GSA Capital Partners LLP’s holdings in Castle Biosciences were worth $1,162,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. RiverPark Advisors LLC lifted its position in Castle Biosciences by 362.2% during the 1st quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock worth $63,000 after buying an additional 2,242 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Castle Biosciences by 351.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,110 shares of the company’s stock worth $67,000 after purchasing an additional 2,421 shares in the last quarter. Assetmark Inc. grew its stake in shares of Castle Biosciences by 21.3% during the fourth quarter. Assetmark Inc. now owns 4,736 shares of the company’s stock valued at $102,000 after purchasing an additional 832 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Castle Biosciences by 943.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 5,739 shares of the company’s stock valued at $124,000 after purchasing an additional 5,189 shares in the last quarter. Finally, WuXi AppTec Co. Ltd. bought a new position in Castle Biosciences in the 4th quarter worth approximately $143,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 2,368 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $23.40, for a total transaction of $55,411.20. Following the sale, the insider now directly owns 57,893 shares of the company’s stock, valued at approximately $1,354,696.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Castle Biosciences news, insider Derek J. Maetzold sold 2,368 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $23.40, for a total value of $55,411.20. Following the sale, the insider now owns 57,893 shares in the company, valued at approximately $1,354,696.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel Bradbury sold 23,323 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $24.64, for a total value of $574,678.72. Following the transaction, the director now owns 9,981 shares of the company’s stock, valued at $245,931.84. The disclosure for this sale can be found here. Insiders sold a total of 30,427 shares of company stock valued at $736,715 over the last quarter. 7.20% of the stock is owned by corporate insiders.

Castle Biosciences Stock Performance

Shares of CSTL remained flat at $17.85 on Wednesday. 99,319 shares of the company were exchanged, compared to its average volume of 259,443. Castle Biosciences, Inc. has a twelve month low of $12.07 and a twelve month high of $25.91. The stock has a market cap of $492.84 million, a PE ratio of -15.52 and a beta of 0.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.25 and a quick ratio of 9.02. The stock’s 50 day simple moving average is $22.79 and its 200 day simple moving average is $21.93.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.28. Castle Biosciences had a negative return on equity of 7.91% and a negative net margin of 12.28%. The business had revenue of $72.97 million during the quarter, compared to analysts’ expectations of $68.34 million. Equities research analysts predict that Castle Biosciences, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Robert W. Baird reiterated an “outperform” rating and issued a $34.00 price objective on shares of Castle Biosciences in a research report on Friday, July 5th.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.